THE APEX TIMES
Johnson & Johnson Earns 5-Star Spot in Newsweek’s World’s Greenest Companies 2026
The healthcare giant was among a group of top-scoring firms cited by Newsweek and Plant-A Insights Group as part of a new environmental sustainability ranking released June 4.
Johnson & Johnson was named among the 5-star winners in Newsweek’s World’s Greenest Companies 2026, a ranking that identifies the top 850 publicly listed companies across 28 countries based on environmental sustainability performance, according to a June 4 announcement. The recognition places the company alongside firms including Goldman Sachs, MetLife, Ralph Lauren, Hitachi, T-Mobile and Zillow, the release said.
Newsweek and Plant-A Insights Group said the 2026 ranking draws on self-disclosed sustainability data and independent research. The study screened more than 8,000 companies before selecting the 850 highest-scoring names for inclusion. The evaluation used information “available up to April 2026,” and it considered only companies whose latest sustainability data were published on or after January 31, 2025, the release stated.
The ranking’s scoring approach relies on analysis across more than 25 parameters organized into four categories: greenhouse gas (GHG) emissions, water usage, waste generation, and sustainability data disclosure and commitments. Newsweek said the assessment also incorporated EU Benchmark exclusion criteria and applied exclusions for certain activity types and controversies, including involvement in controversial weapons, nuclear energy, tobacco, major fossil fuel activities, or environmental misconduct. The release also said companies with fewer than 500 employees were excluded and that Newsweek and Plant-A verified exclusions through media monitoring and review.
A separate Plant-A project page describing the same initiative says the companies are evaluated and scored on more than 25 parameters spanning those four categories. It also says the group used an industry media monitoring platform to screen press coverage for potential issues tied to greenwashing, corporate fraud, regulatory violations, and environmental disasters. The page further states that all winners’ scores and details were verified by Plant-A’s research team and Newsweek’s editorial and rankings team, and that Plant-A maintains a “no-pay-to-play” policy, with no applications required.
For Johnson & Johnson specifically, the company markets its sustainability strategy under its “Health for Humanity” environmental sustainability effort. In its climate action materials, J&J says it reduced the carbon footprint of its operations by 23% between 2021 and 2023. It also reports that 87% of its electricity needs came from renewable sources over that period, and that it reached 100% renewable electricity in the U.S., Canada and Europe. The company also said it avoided approximately 265,000 metric tons of carbon emissions annually through efficiency projects completed between 2005 and 2023.
J&J’s disclosures also describe a continued push toward renewable energy and decarbonization, including an objective to increase renewable electricity usage with a “goal to reach 100% by 2025.” The company also cites efforts aimed at fleet electrification and supplier engagement on decarbonization strategies, and it references a “CO2 Capital Relief Program” described as continued investment of up to $40 million per year in low-carbon technologies and operational energy efficiency. Those items speak to the types of emissions, operational efficiency, and disclosure topics that environmental rankings typically weight heavily.
Even with the new recognition, the public release does not disclose Johnson & Johnson’s specific score, category breakdown, or whether its 5-star designation reflects particular year-over-year improvements versus overall standing. The Newsweek methodology summary also emphasizes that scores are derived from publicly available sustainability reporting, which means differences in how companies measure and report data can affect comparability across industries. What is clear is that the ranking is centered on disclosed sustainability metrics, screened by eligibility rules and exclusion criteria, and capped at the top-scoring 850 firms worldwide.
Why It Matters
- For large consumer and healthcare brands, sustainability rankings can influence procurement discussions and reputation assessments, even when they are not tied to regulatory outcomes.
- The Newsweek methodology underscores that public sustainability reporting quality and completeness may be a key driver of inclusion and scoring.
- Recognition alongside finance and consumer companies highlights that cross-industry environmental metrics are being treated as a mainstream corporate benchmark.
- Because the release does not provide Johnson & Johnson’s category scorecard, investors and analysts may still need to rely on the company’s own sustainability reporting for verification of progress.
Sources
- announcement (Yahoo Finance RSS copy of GlobeNewswire release)
- GlobeNewswire: Newsweek and Plant-A release detailing World’s Greenest Companies 2026 methodology and winners
- Plant-A Insights Group project page for World’s Greenest Companies 2026 methodology overview
- Johnson & Johnson: Health for Humanity global environmental sustainability goals page
- Image
Key Facts
- Newsweek, in partnership with Plant-A Insights Group, announced its World’s Greenest Companies 2026 rankings, recognizing the top 850 publicly listed firms across 28 countries.
- Johnson & Johnson was cited among the publication’s 5-star winners in the 2026 list.
- The ranking is based on self-disclosed sustainability data and independent research, using information available up to April 2026.
- Companies were required to have their latest sustainability data published on or after January 31, 2025, to be considered eligible.
- Scoring categories include greenhouse gas emissions, water usage, waste generation, and sustainability data disclosure and commitments.
- Newsweek and Plant-A applied EU Benchmark exclusion criteria and excluded companies with fewer than 500 employees.
Healthcare Related
Bristol-Myers Squibb screens cheaper than Johnson & Johnson, but leverage and patent overhang drive the debate
A market analysis comparing Bristol-Myers Squibb and Johnson & Johnson in 2026 points to a valuation gap, while warning that BMY’s financial leverage and patent risks could outweigh its cheaper price. JNJ’s case rests on its diversified business model.
Moderna Shares Slip as Biotech Pullback Spurs Caution, Investors Told Not to Overreact
A market-wide retreat in biotech stocks is weighing on Moderna, but analysts cited upcoming company and partner catalysts that could help stabilize sentiment.
Pfizer set to report Q3 2026 earnings next month, with analysts bracing for profit decline
Ahead of Pfizer’s third-quarter 2026 results, market watchers are preparing for a double-digit dip in profit, underscoring how sensitive the company’s earnings outlook remains to new-product growth and shifting demand.
Pfizer extends dividend streak to 352 straight quarters, but questions linger on sustainability
Pfizer announced another quarterly payout, marking a long run of uninterrupted dividends. A key debate for investors is whether the current yield can be maintained as the company navigates patent cliffs, pipeline execution, and generics competition.
Eli Lilly bulls shift focus from Zepbound to pipeline, arguing newer drugs could drive the next growth cycle
A recent market commentary from Yahoo Finance urged investors to look past Zepbound and toward Eli Lilly’s broader drug discovery engine, citing three newer medicines as potential drivers.
A $1,000 Bet on Eli Lilly Turned Into $18,637, Highlighting How One Obesity Drug Reshaped the Market
A recent market-focused analysis argues that Eli Lilly’s transition from an insulin-dominant history to obesity blockbuster status transformed not just the company, but also how investors think about the category.
Q2 hospital-chain stock spotlight: Yahoo Finance compares HCA Healthcare with peers as earnings season ends
A new Yahoo Finance wrap-up looks across hospital operators to identify which hospital-chain stocks stood out and which lagged during the latest quarterly earnings cycle, placing HCA Healthcare in the peer set.
Johnson & Johnson outlines a growth reset as pharma strength offsets sluggish MedTech
A recent market-focused review points to uneven performance across Johnson & Johnson’s businesses, with pharmaceutical momentum helping compensate for stalled MedTech growth, alongside a strategy built around new product launches and a planned spin-off.
Pfizer’s discount to AbbVie is widening the valuation question in pharma’s core medicines
A Yahoo Finance comparison highlights how Pfizer’s lower share price has investors weighing whether the market is pricing in real fundamental risk or simply valuing different mixes of profitable drugs.
UnitedHealth Q3 margins improved, but shrinking membership puts pressure on the growth narrative
A reported jump in profit margins came alongside falling membership in UnitedHealth’s latest quarter, reviving questions about how durable the company’s operating turnaround will be.